Get the Stockscreener App
0.8877
8.81%
-0.0858
After Hours:
.94
0.0523
+5.89%
Longeveron Inc stock is traded at $0.8877, with a volume of 25.35M.
It is down -8.81% in the last 24 hours and up +65.68% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$0.9735
Open:
$1.075
24h Volume:
25.35M
Relative Volume:
5.20
Market Cap:
$18.94M
Revenue:
$1.44M
Net Income/Loss:
$-21.34M
P/E Ratio:
-0.6639
EPS:
-1.3371
Net Cash Flow:
$-17.38M
1W Performance:
+67.65%
1M Performance:
+65.68%
6M Performance:
+18.45%
1Y Performance:
-47.47%
1-Day Range:
$0.8795
$1.22
1-Week Range:
$0.5928
$1.22
52-Week Range:
$0.475
$1.9198
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.8877 | 20.77M | 1.44M | -21.34M | -17.38M | -1.3371 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.10 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.91 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.30 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.91 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
289.65 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Longeveron’s Stem Cell Therapy Boosts Physical Function, Spurs Market Interest - timothysykes.com
Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 Results - GuruFocus
Longeveron Hits Milestones in Phase 2b Trial and CEO Transition - timothysykes.com
Longeveron Stock on a Rollercoaster: Clinical Trials and CEO Appointment Fuel Market Interest - StocksToTrade
LGVN Longeveron Inc. (NASDAQ) +20% to $0.97 Mar 13, 2026: earnings, runway - Meyka
Zacks Research Predicts Increased Earnings for Longeveron - Defense World
Longeveron Expands CEO Roster Amid Positive Phase 2 Trial Outcomes - StocksToTrade
Longeveron Announces $30 Million Private Placement Financing - TipRanks
Best Biotech Stocks To Keep An Eye On – March 10th - Defense World
Longeveron closes $15 million financing, extends runway to 4Q26 - Investing.com Australia
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 - Bitget
Longeveron closes $15 million financing, extends runway to 4Q26 By Investing.com - Investing.com South Africa
Longeveron Announces Closing of Private Placement of up to $30 Million - Bitget
Biotech Longeveron secures $15M, cash runway past 2026 HLHS trial readout - Stock Titan
A $30 Million Reason to Buy Penny Stock Longeveron Today - Yahoo Finance
Longeveron secures $15M financing with potential for additional $15M tied to trial milestones - MSN
Longeveron secures $15M financing, eyes $15M more on trial results By Investing.com - Investing.com South Africa
Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal - Benzinga
Longeveron Inc. (LGVN) Stock: Surges 60% as Company Secures $30M Private Placement Funding - parameter.io
LGVN Longeveron (NASDAQ) +97.64% intraday 10 Mar 2026: earnings 12 Mar to watch - Meyka
Longeveron prices 6.01M shares at 52c in private placement - TipRanks
Longeveron jumps 70.7% as investors react to up to $30M private placement financing - Quiver Quantitative
Biotech Stock Longeveron Inc. (NASDAQ: LGVN) Makes Nasdaq Top Gainer List on News - Investorideas.com
Longeveron secures $15M financing, eyes $15M more on trial results - Investing.com India
Longeveron secures $15M now, another $15M tied to HLHS trial milestones - Stock Titan
LGVN: Company Fortifies Funding - Research Tree
Block Trades: Can Longeveron Inc outperform in the next rally2026 Technicals & Consistent Growth Equity Picks - baoquankhu1.vn
Longeveron Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Longeveron (NASDAQ: LGVN) director resigns, triggering and addressing Nasdaq audit committee issue - Stock Titan
Merger Talk: How cyclical is Longeveron Incs revenue streamLayoff News & Technical Pattern Based Buy Signals - baoquankhu1.vn
Aug Sentiment: Is Longeveron Inc exposed to currency risks2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Cantech Letter
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Longeveron Inc. (LGVN) asks shareholders to OK 1:5–1:20 reverse split to meet Nasdaq - Stock Titan
LGVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LGVN: Trial Results Encouraging - Research Tree
LGVN Should I Buy - Intellectia AI
Longeveron Reports Positive Phase 2b Clinical Trial Results - Intellectia AI
Longeveron Inc. Reports Positive Trial Results for Age-Related Therapy - Intellectia AI
Longeveron Shares Fall After Releasing Phase 2b Data From Age-Related Frailty Study - marketscreener.com
Longeveron publishes phase 2b stem cell trial results in journal - Investing.com
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty In Study - Stocktwits
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - Bitget
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - The Manila Times
Stem cell therapy helps frailty patients walk farther in Longeveron trial - Stock Titan
Aug Movers: Can Longeveron Inc outperform in the next rallyEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Q1 Earnings Forecast for Longeveron Issued By Zacks Research - Defense World
Will Longeveron Inc. stock hit new highs in YEARMarket Performance Recap & Intraday High Probability Alerts - mfd.ru
Longeveron (LGVN) Projected to Post Quarterly Earnings on Friday - Defense World
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):